|
1
|
Xavier RJ and Podolsky DK: Unravelling the
pathogenesis of inflammatory bowel disease. Nature. 448:427–434.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sartor RB: Pathogenesis and immune
mechanisms of chronic inflammatory bowel diseases. Am J
Gastroenterol. 92 12 Suppl:5S–11S. 1997.PubMed/NCBI
|
|
3
|
Saeed SA and Kugathasan S: Epidemiology of
pediatric inflammatory bowel disease. Pediatr Inflam Bowel Dis.
71–86. 2017.
|
|
4
|
Singh UP, Singh NP, Busbee B, Guan H,
Singh B, Price RL, Taub DD, Mishra MK, Nagarkatti M and Nagarkatti
PS: Alternative medicines as emerging therapies for inflammatory
bowel diseases. Int Rev Immunol. 31:66–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiel S, Vorup-Jensen T, Stover CM,
Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen
S, Holmskov U, et al: A second serine protease associated with
mannan-binding lectin that activates complement. Nature.
386:506–510. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mastellos DC, Ricklin D, Hajishengallis E,
Hajishengallis G and Lambris JD: Complement therapeutics in
inflammatory diseases: Promising drug candidates for C3-targeted
intervention. Mol Oral Microbiol. 31:3–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo RF and Ward PA: Role of C5a in
inflammatory responses. Annu Rev Immunol. 23:821–852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Czermak BJ, Sarma V, Bless NM, Schmal H,
Friedl HP and Ward PA: In vitro and in vivo dependency of chemokine
generation on C5a and TNF-alpha. J Immunol. 162:2321–2325.
1999.PubMed/NCBI
|
|
9
|
Mollnes TE, Brekke OL, Fung M, Fure H,
Christiansen D, Bergseth G, Videm V, Lappegård KT, Köhl J and
Lambris JD: Essential role of the C5a receptor in E coli-induced
oxidative burst and phagocytosis revealed by a novel
lepirudin-based human whole blood model of inflammation. Blood.
100:1869–1877. 2002.PubMed/NCBI
|
|
10
|
Dang L, He L, Wang Y, Xiong J, Bai B and
Li Y: Role of the complement anaphylatoxin C5a-receptor pathway in
atopic dermatitis in mice. Mol Med Rep. 11:4183–4189. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bamberg CE, Mackay CR, Hyun L, Zahra D,
Jackson J, Lim YS, Whitfeld PL, Craig S, Corsini E, Lu B, Gerard C
and Gerard NP: The C5a receptor (C5aR) C5L2 is a modulator of
C5aR-mediated signal transduction. J Biol Chem. 285:7633–7644.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Rollins SA, Madri JA and Matis LA:
Anti-C5 monoclonal antibody therapy prevents collagen-induced
arthritis and ameliorates established disease. Proc Natl Acad Sci
USA. 92:pp. 8955–8959. 1995, View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Makrides SC: Therapeutic inhibition of the
complement system. Pharmacol Rev. 50:59–87. 1998.PubMed/NCBI
|
|
14
|
Kaur G and Roy I: Therapeutic applications
of aptamers. Expert Opin Investig Drugs. 17:43–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Parashar A: Aptamers in therapeutics. J
Clin Diagn Res. 10:BE01–BE06. 2016.PubMed/NCBI
|
|
16
|
Jain U, Otley AR, Van Limbergen J and
Stadnyk AW: The complement system in inflammatory bowel disease.
Inflamm Bowel Dis. 20:1628–1637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rioux JD, Silverberg MS, Daly MJ,
Steinhart AH, McLeod RS, Griffiths AM, Green T, Brettin TS, Stone
V, Bull SB, et al: Genomewide search in Canadian families with
inflammatory bowel disease reveals two novel susceptibility loci.
Am J Hum Genet. 66:1863–1870. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Speidl WS: Atherosclerosis and complement:
Anaphylatoxin C5a as a new risk marker and therapeutic target. Clin
Lipidol. 6:123–126. 2011. View
Article : Google Scholar
|
|
19
|
Holers VM: Complement and its receptors:
New insights into human disease. Annu Rev Immunol. 32:433–859.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gasque P: Complement: A unique innate
immune sensor for danger signals. Mol Immunol. 41:1089–1098. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dempsey PW, Allison ME, Akkaraju S,
Goodnow CC and Fearon DT: C3d of complement as a molecular
adjuvant: Bridging innate and acquired immunity. Science.
271:348–350. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogden CA and Elkon KB: Role of complement
and other innate immune mechanisms in the removal of apoptotic
cells. Curr Dir Autoimmun. 9:120–142. 2006.PubMed/NCBI
|
|
23
|
Woodruff TM, Ager RR, Tenner AJ, Noakes PG
and Taylor SM: The role of the complement system and the activation
fragment C5a in the central nervous system. Neuromolecular Med.
12:179–192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo RF, Riedemann NC and Ward PA: Role of
C5a-C5aR interaction in sepsis. Shock. 21:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee T, Lee E, Irwin R, Lucas PC, McCabe LR
and Parameswaran N: β-Arrestin-1 deficiency protects mice from
experimental colitis. Am J Pathol. 182:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Margonis GA, Christoloukas N, Antoniou E,
Arkadopoulos N, Theodoropoulos G, Agrogiannis G, Pikoulis E,
Patsouris ES, Zografos GC and Papalois AE: Effectiveness of
sildenafil and U-74389G in a rat model of colitis. J Surg Res.
193:667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Afif W and Loftus EV Jr: Safety profile of
IBD therapeutics: Infectious risks. Gastroenterol Clin North Am.
38:691–709. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Keefe AD, Pai S and Ellington A: Aptamers
as therapeutics. Nat Rev Drug Discov. 9:537–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hermann T and Patel DJ: Adaptive
recognition by nucleic acid aptamers. Science. 287:820–825. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nimjee SM, Rusconi CP and Sullenger BA:
Aptamers: An emerging class of therapeutics. Annu Rev Med.
56:555–583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cunningham ET Jr, Adamis AP, Altaweel M,
Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B,
Patel M, et al: A phase II randomized double-masked trial of
pegaptanib, an anti-vascular endothelial growth factor aptamer, for
diabetic macular edema. Ophthalmology. 112:1747–1757. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bunka DH, Platonova O and Stockley PG:
Development of aptamer therapeutics. Curr Opin Pharmacol.
10:557–562. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dobrovolsky AB, Titaeva EV, Khaspekova SG,
Spiridonova VA, Kopylov AM and Mazurov AV: Inhibition of thrombin
activity with DNA-aptamers. Bull Exp Biol Med. 148:33–36. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rusconi CP, Scardino E, Layzer J, Pitoc
GA, Ortel TL, Monroe D and Sullenger BA: RNA aptamers as reversible
antagonists of coagulation factor IXa. Nature. 419:90–94. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kubik MF, Bell C, Fitzwater T, Watson SR
and Tasset DM: Isolation and characterization of 2′-fluoro-,
2′-amino-, and 2′-fluoro-/amino-modified RNA ligands to human
IFN-gamma that inhibit receptor binding. J Immunol. 159:259–267.
1997.PubMed/NCBI
|
|
36
|
Li N, Nguyen HH, Byrom M and Ellington AD:
Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One.
6:e202992011. View Article : Google Scholar : PubMed/NCBI
|
